Scientists in Germany say they've successfully created a nasal vaccine that can effectively prevent Covid-19 infections by targeting the virus's entry point in the nose and throat. In hamster studies, two doses of this live but weakened nasal vaccine demonstrated "sterilizing immunity" and prevented illness, achieving what was previously thought to be an impossible goal.
The vaccine works by boosting mucosal immunity, beefing up immune defenses in the tissues that line the upper airways, where the virus enters the body. This approach mimics the process of a natural infection, making it more effective than traditional vaccines that only target specific proteins on the surface of the virus.
Researchers used a technique called codon pair deoptimization to weaken the genetic material in the virus, rendering it harmless while still allowing the immune system to recognize and fight it off. This method is based on modifying the genetic code of the virus so that cells have difficulty translating its instructions.
The results are promising, with the nasal vaccine outperforming other vaccines in animal studies. The vaccine also previews the entire coronavirus for the body, making it possible to create immune weapons against a wider range of targets.
However, experts caution that more testing is needed before this vaccine can be widely used. "It's still a long way off," said Dr. Greg Poland, who designs vaccines at the Mayo Clinic. "We should be developing a pan-coronavirus vaccine that induces mucosal immunity and is long-lived."
At least four nasal vaccines for Covid-19 are currently in late-stage testing in humans, according to the World Health Organization's vaccine tracker. Another nasal vaccine, developed by Codagenix, is nearing completion of human studies.
While some live vaccines have shown promise, others have proven to be less effective due to compromised immunity. Researchers will need to carefully consider these factors when evaluating the safety and efficacy of this new nasal vaccine.
The development of a pan-coronavirus vaccine that can induce mucosal immunity has the potential to revolutionize our approach to Covid-19 prevention and treatment. As researchers continue to work towards this goal, they must remain vigilant in their pursuit of a safe and effective solution for the ongoing pandemic.
The vaccine works by boosting mucosal immunity, beefing up immune defenses in the tissues that line the upper airways, where the virus enters the body. This approach mimics the process of a natural infection, making it more effective than traditional vaccines that only target specific proteins on the surface of the virus.
Researchers used a technique called codon pair deoptimization to weaken the genetic material in the virus, rendering it harmless while still allowing the immune system to recognize and fight it off. This method is based on modifying the genetic code of the virus so that cells have difficulty translating its instructions.
The results are promising, with the nasal vaccine outperforming other vaccines in animal studies. The vaccine also previews the entire coronavirus for the body, making it possible to create immune weapons against a wider range of targets.
However, experts caution that more testing is needed before this vaccine can be widely used. "It's still a long way off," said Dr. Greg Poland, who designs vaccines at the Mayo Clinic. "We should be developing a pan-coronavirus vaccine that induces mucosal immunity and is long-lived."
At least four nasal vaccines for Covid-19 are currently in late-stage testing in humans, according to the World Health Organization's vaccine tracker. Another nasal vaccine, developed by Codagenix, is nearing completion of human studies.
While some live vaccines have shown promise, others have proven to be less effective due to compromised immunity. Researchers will need to carefully consider these factors when evaluating the safety and efficacy of this new nasal vaccine.
The development of a pan-coronavirus vaccine that can induce mucosal immunity has the potential to revolutionize our approach to Covid-19 prevention and treatment. As researchers continue to work towards this goal, they must remain vigilant in their pursuit of a safe and effective solution for the ongoing pandemic.